Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of blood cancer called chronic phase CML, where a particular genetic marker (called Philadelphia chromosome-positive and/or BCR-ABL-positive) is present
• People who started their first-ever treatment for this condition using a type of medication called TKIs (targeted therapy drugs), between 1 January 2015 and 31 January 2022
• People who were aged between 18 and 75 years old at the time they started that treatment
• People who are male
• People who had taken certain medications (Hydroxyurea or Anagrelide) before starting TKI therapy — this is permitted
• People who are able to understand the study's goals and procedures and can make a free and voluntary choice about taking part
• People who have signed a written consent form in line with required legal and ethical standards

Who may not be able to join:

• People whose CML has progressed to a more advanced stage (known as accelerated phase or blast phase)
• People who experienced a specific condition before starting TKI treatment (confirm with trial site for full details, as the condition is noted in the criteria but context is limited)

Important: Always verify eligibility with the trial site directly before applying.